Pasithea Therapeutics Cor... (KTTA)
NASDAQ: KTTA
· Real-Time Price · USD
0.77
-0.02 (-2.04%)
At close: Jun 16, 2025, 11:34 AM
-2.04% (1D)
| Bid | 0.76 |
| Market Cap | 5.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.57B |
| EPS (ttm) | -10.38 |
| PE Ratio (ttm) | -0.07 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.77 |
| Volume | 155,342 |
| Avg. Volume (20D) | 6,165,688 |
| Open | 0.77 |
| Previous Close | 0.79 |
| Day's Range | 0.71 - 0.77 |
| 52-Week Range | 0.71 - 7.50 |
| Beta | 0.34 |
About KTTA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KTTA
Website n/a
1 month ago
+11.09%
Pasithea Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
1 month ago
+11.07%
Pasithea Therapeutics shares are trading higher after the company announced initiation of its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004, in adult participants with neurofibromatosis type 1 with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas.
